What are the doses of Benztropine (Benztropine mesylate)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the FDA Drug Label

DOSAGE AND ADMINISTRATION Benztropine mesylate tablets should be used when patients are able to take oral medication. ... Increases should be made in increments of 0. 5 mg, to a maximum of 6 mg, or until optimal results are obtained without excessive adverse reactions. Postencephalitic and Idiopathic Parkinsonism - The usual daily dose is 1 to 2 mg, with a range of 0. 5 to 6 mg orally or parentally. Drug-Induced Extrapyramidal Disorders - In treating extrapyramidal disorders due to neuroleptic drugs (e.g., phenothiazines), the recommended dosage is 1 to 4 mg once or twice a day orally, or parenterally.

The recommended benztropine doses are:

  • Postencephalitic and Idiopathic Parkinsonism: 1 to 2 mg daily, with a range of 0.5 to 6 mg orally or parentally 1
  • Drug-Induced Extrapyramidal Disorders: 1 to 4 mg once or twice a day orally, or parenterally 1, 1 The dose should be individualized according to the need of the patient, and increased gradually at five or six-day intervals to the smallest amount necessary for optimal relief. Key points:
  • The maximum dose is 6 mg
  • Increases should be made in increments of 0.5 mg
  • The dose should be adjusted to obtain optimal results without excessive adverse reactions 1

From the Research

Benztropine is typically dosed at 1-2 mg orally once or twice daily for the treatment of Parkinson's disease and drug-induced extrapyramidal symptoms. For acute dystonic reactions, 1-2 mg can be given intramuscularly or intravenously. Treatment should start with lower doses (0.5-1 mg) in elderly patients and those who are more sensitive to anticholinergic effects. The maximum daily dose should not exceed 6 mg. Benztropine works by blocking cholinergic receptors in the central nervous system, which helps restore the balance between dopamine and acetylcholine in the basal ganglia. This medication should be taken consistently at the same time each day to maintain therapeutic levels. Patients should be monitored for anticholinergic side effects including dry mouth, blurred vision, constipation, urinary retention, and confusion. Benztropine should be used cautiously in patients with glaucoma, prostatic hypertrophy, or cognitive impairment, and should not be abruptly discontinued as this may worsen parkinsonian symptoms.

Some key points to consider when using benztropine include:

  • The medication should be used with caution in patients with certain medical conditions, such as glaucoma or prostatic hypertrophy 2
  • Benztropine can cause anticholinergic side effects, which can be problematic in elderly patients or those with certain medical conditions 3
  • The medication can be effective in treating drug-induced parkinsonism, but may not be effective in treating other forms of parkinsonism, such as idiopathic Parkinson's disease 4
  • Benztropine should not be used in combination with other medications that can cause anticholinergic effects, as this can increase the risk of side effects 5

It's also important to note that benztropine is not a disease-modifying treatment, but rather a symptomatic treatment that can help improve motor and nonmotor symptoms in patients with Parkinson's disease 2. Overall, benztropine can be a useful medication for treating Parkinson's disease and drug-induced extrapyramidal symptoms, but should be used with caution and under the guidance of a healthcare professional.

References

Research

Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective.

Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 1999

Research

Drug-induced Parkinson`s disease. A clinical review.

Neurosciences (Riyadh, Saudi Arabia), 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.